Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Journal of Analytical Research in Clinical Medicine
   eISSN: 2345-4970  
Services
Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks
Mendeley

Cite by
Google Scholar



Article History
Submitted: 11 Aug 2017
Accepted: 24 Sep 2017
First published online: 24 Sep 2017

Article Access Statistics
Abstract Page Views: 15
PDF Downloads: 80
Full Text Views: 0

J Anal Res Clin Med. 2017;5(4):112-117 doi: 10.15171/jarcm.2017.022

Study on the prognostic value of p53 and PTEN immunomarkers for endometrial cancer using immunohistochemistry

Original Article

Heidar Ali Esmaieli 1 * , Haniyeh Amidfar 1, Elmira Mostafidi 1, Atieh Amidfar 1

1 Department of General Pathology, School of Medicine, Tabriz University of Medical Science, Tabriz, Iran



Abstract
Introduction: Mutation in p53 and phosphatase and tensin homolog (PTEN) genes are reported to be prevalent in endometrial cancer. The present study aimed to evaluate the immunohistochemical expression of p53 and PTEN proteins in endometrial cancer among women with hysterectomy. Methods: In this cross-sectional study, 40 paraffin-embedded endometrial cancer samples were collected during 2015 to 2016, from women with hysterectomy in Al Zahra Hospital, Tabriz, Iran. The histopathological observation was performed to confirm endometrial cancer and its grade. Immunohistochemistry (IHC) was done for p53 and PTEN biomarkers. Data were analyzed by SPSS. Results: Thirty-three (82.5%), six (15.0%) and one (2.5%) out of 40 samples were endometrioid endometrial adenocarcinoma, serous carcinoma and clear cell adenocarcinoma, respectively. Furthermore, 5, 16 and 19 out of 40 studied samples belonged to grade I, II and III, respectively. The IHC observation showed that p53 expression in 9 (22.5%) was positive, while the rest 31 (77.5%) samples were p53 negative. Moreover, PTEN expression was observed in 10 (25%) samples and 30 (75.0%) samples were PTEN negative. The sensitivity of p53 and PTEN for diagnosis of endometrial cancer was calculated as 56.3% and 80%, respectively. Conclusion: The IHC markers, p53 and PTEN, show heterogeneous results as diagnostic and prognostic markers for endometrial carcinoma and are suggested to be used along with other markers for such purposes.





Comments
First name  
Last name  
Email address  
Comments  
Security code



This Article
PDF

Google Scholar
Articles by Esmaieli HA
Articles by Amidfar H
Articles by Mostafidi E
Articles by Amidfar A

PubMed
Articles by Esmaieli HA
Articles by Amidfar H
Articles by Mostafidi E
Articles by Amidfar A



Share this article!
© 2017 Tabriz University of Medical Sciences; unless otherwise stated.

Press Manuscript Online. Powered by MAADRAYAN